Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AL-335
AL-335
J&J advances through PhII with a promising hep C triple and 100% cure rate
Endpoints
Fri, 09/9/16 - 10:21 am
JNJ
hepatitis C
clinical trials
odalasvir
AL-335
Olysio
Achillion
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St
Sat, 09/3/16 - 12:17 pm
FDA
Achillion
odalasvir
AL-335
simeprevir
Amarin
Vascepa
Array Biopharma
binimetinib
Mast Therapeutics
vepoloxamer
Novavax
Threshold Pharmaceuticals
tarloxotinib